

DPP-4 Inhibitors

Their Place in Type 2 Diabetes Treatment

&


New Guidelines

Objectives

- DPP-4 inhibitors in ADA guideline
- DPP-4 inhibitors Mechanism of Action
- Sitagliptin Efficacy
- Linagliptin Efficacy
- Diabetes Guidelines (ADA 2021 and AACE)
- Conclusion



INDICATORS OF HIGH-RISK OR ESTABLISHED ASCVD. CKD. OR HF⁺



6. Empagilflozin, canagilflozin, and dapagilflozin have shown reduction in HF and to reduce CKD progression in CVOTs. Canagliflozin and dapagliflozin have primary renal outcome data. Dapagliflozin and empaglificzin have primary heart failure outcome data.

+ASCVD/Indicators

of High Risk

carotid, or lower-extremity

Established ASCVD

ASCVD risk (age ≥55

artery stenosis >50%,

ETTHERV

OR

If A1C above target

If further intensification

is required or patient is

unable to tolerate GLP-1 RA and/or SGLT2i, choose

agents demonstrating

CV benefit and/or safety:

GLP-1 RA, consider

adding SGLT2i with

proven CVD benefit

For patients on a

and vice versa1

DPP-4i if not on

GLP-1 RA

Basal insulin³

TZD²

SU⁴

SGLT2i

with

proven

CVD

benefit¹

years with coronary,

Indicators of high

or LVH)

GLP-1

RA with

proven

CVD

benefit¹

Diabetes Care 2021; 44(Suppl. 1):S111-S124.


relatively cheaper.

countries TZDs are relatively more expensive and DPP-4i are

glucose-lowering medications.

glucose-lowering therapy.


* Most patients enrolled in the relevant trials were on metformin at baseline as



• DPP-4 inhibitors Mechanism of Action




DPP-4 Inhibitors Improve Glucose Control by Increasing Incretin Levels in Type 2 Diabetes¹⁻⁴



DPP-4 = dipeptidyl peptidase 4

1-Endocrinology. 2004 ;145(6):2653-9. 2- Lancet. 2002 ;359(9309):824-30; 3-Curr Diab Rep. 2003;3(5):365-72; 4-Buse JB et al. In Williams Textbook of Endocrinology. 10th ed., 2003:1427–1483.


The Effect of Incretins in Type 2 Diabetes and Non-Diabetes¹



• Sitagliptin Efficacy




Sitagliptin Consistently and Significantly Lowers A1C With Once-Daily **Dosing in Monotherapy**



DIABETES

1. Diabetes Care. 2006;29(12):2632-7. 2- Diabetes Res Clin Pract. 2008;79(2):291-8. 3. Diabetologia. 2006;49(11):2564-71.

Glucose Control With Sitagliptin in Different Studies



**P*<0.001 vs active comparator monotherapy. ⁺*P*<0.001 vs active comparator dual therapy. # Compare to placebo. Met: Metformin; Sit= Sitagliptin; Glip=Glipizide; Ins=Insulin; Pio=Pioglitazone, Rosi=Rosiglitazone .

1. Diabetes Obes Metab. 2007 ;9(2):194-205; 2. Diabetes Care. 2007 ;30(8):1979-87. 3. Diabetes Care. 2006;29(12):2638-43.;4. Diabetes Obes Metab. 2010;12(2):167-77. 5. Metabolism. 2010 ;59(6):887-95.; 6. J Diabetes. 2013r;5(1):68-79

EXPERIMENTAL AND THERAPEUTIC MEDICINE 9: 1528-1536, 2015

Efficacy and safety of sitagliptin compared with sulfonylurea therapy in patients with type 2 diabetes showing inadequately controlled glycosylated hemoglobin with metformin monotherapy: A meta-analysis

LIQIONG HOU, TIEYUN ZHAO, YUNHUI LIU and YIYI ZHANG

Department of Endocrinology and Metabolism, West China Hospital of Sichuan University, Chengdu, Sichuan 610000, P.R. China


Received June 18, 2014; Accepted January 26, 2015

childi DIABETES

Hba1c Changes Were not Significant Between Sitagliptin and Sulfonylurea Groups¹

	sitagliptin			Sulfonylurea			Mean Difference		Mean Difference	
Study or Subgroup	Mean		Total	Mean	SD	Total	Weight	IV, Random, 95% Cl	IV, Random, 95% Cl	
1.4.1 sitagliptin versu	ıs glimep	oiride								
Arechavaleta 2011	-0.47	0.86	443	-0.54	0.91	436	25.0%	0.07 [-0.05, 0.19]	† ≡−	
Li 2012	-2.4	0.8	58	-2.1	0.8	58	12.4%	-0.30 [-0.59, -0.01]		
Srivastava 2012	-0.64	0.99	25	-1.17	0.25	25	8.1%	0.53 [0.13, 0.93]		
Subtotal (95% CI)			526			519	45.5%	0.07 [-0.28, 0.43]		
Heterogeneity: Tau ² =	0.08; Ch	i ² = 11.	18, df	= 2 (P =	0.004); I ² = 8	2%			
Test for overall effect:	Z=0.41	(P = 0.0)	68)							
1.4.2 sitagliptin versu	ıs glipizio	de								
Nauck 2007	-0.67	0.8	382	-0.67	0.83	411	25.3%	0.00 [-0.11, 0.11]	+	
Seck 2010	-0.54	0.76	248	-0.51	0.73	256	23.9%	-0.03 [-0.16, 0.10]		
Subtotal (95% CI)			630			667	49.2%	-0.01 [-0.10, 0.07]	•	
Heterogeneity: Tau ² =	0.00: Ch	ni ² = 0.1	2. df =	1 (P = 1)	0.73): I	² = 0%				
Test for overall effect:	-		-		,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,					
1.4.3 sitagliptin versu	ıs aliben	clamid	e							
Shlomit Koren 2012		1.1	34	-1	1.1	34	5.3%	0.40 [-0.12, 0.92]		
Subtotal (95% CI)	0.0		34			34	5.3%	0.40 [-0.12, 0.92]		
Heterogeneity: Not ap	nlicable							,,		
Test for overall effect:			13)							
	2 - 1.00	v = 0.	. 0,							
Total (95% Cl)			1190			1220	100.0%	0.04 [-0.09, 0.17]		
Heterogeneity: Tau² =	0.01; Ch	ni [≥] = 14.	.29, df	= 5 (P =	0.01);	l² = 65	%		-1 -0.5 0 0.5 1	
Test for overall effect:	Z= 0.55	(P = 0.9)	58)					Fa	vors experimental Favors control	
Test for subgroup diffe	erences:	Chi ² =	2.99, 0	df = 2 (P	= 0.22	2), l ² = 3	33.2%	ra	vors experimental Tavors control	

Achievements of <7% HbA1c Target Were not Significant Between Sitagliptin and Sulfonylurea Groups¹




Sitagliptin Groups Did not Experience Weight Gain Compared to Sulfonylurea Groups¹

sitagliptin		Sulf	onylur	ea		Mean Difference	Mean Difference		
Study or Subgroup	bgroup Mean SD Total Mean SD Total Weight IV, Fixed, 95% Cl		IV, Fixed, 95% Cl						
1.5.1 Sitagliptin versu	is glime	piride							
Arechavaleta 2011	-0.8	3.48	516	1.2	3.49	519	4.4%	-2.00 [-2.42, -1.58]	-
Li 2012	-1.2	0.3	58	0.6	0.2	58	92.6%	-1.80 [-1.89, -1.71]	
Subtotal (95% CI)			574			577	97.0%	-1.81 [-1.90, -1.72]	
Heterogeneity: Chi ² =	0.81, df :	= 1 (P :	= 0.37)	² = 0%					
Test for overall effect:	Z = 39.1	1 (P <	0.0000	1)					
1.5.2 Sitagliptin versu	ıs glipizi	de							
Nauck 2007	-1.5	6.78	588	1.1	6.78	584	1.3%	-2.60 [-3.38, -1.82]	
Seck 2010	-1.6	8.04	588	0.7	8.01	584	0.9%	-2.30 [-3.22, -1.38]	
Subtotal (95% Cl)			1176			1168	2.3%	-2.48 [-3.07, -1.88]	•
Heterogeneity: Chi ² =	0.24, df=	= 1 (P =	= 0.62)	; l² = 0%					
Test for overall effect:	Z= 8.18	(P < 0	.00001)					
1.5.3 sitagliptin versu	ls gliben	clamic	le						
Shlomit Koren 2012	-0.2	2	34	1.2	2.3	34	0.8%	-1.40 [-2.42, -0.38]	
Subtotal (95% Cl)			34			34	0.8%	-1.40 [-2.42, -0.38]	•
Heterogeneity: Not ap	plicable								
Test for overall effect:	Z = 2.68	(P = 0	.007)						
restion overall ellect.						1779		-1.82 [-1.91, -1.73]	22.00

SD, standard deviation; CI, confidence interval 1-Exp Ther Med. 2015; 9(4): 1528–1536.

Lower Occurrence of Hypoglycemic Events in Sitagliptin Groups Compared to Sulfonylurea Groups¹



DIABETES

100



The NEW ENGLAND JOURNAL of MEDICINE

ORIGINAL ARTICLE

Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes

Jennifer B. Green, M.D., M. Angelyn Bethel, M.D., Paul W. Armstrong, M.D., John B. Buse, M.D., Ph.D., Samuel S. Engel, M.D., Jyotsna Garg, M.S., Robert Josse, M.B., B.S., Keith D. Kaufman, M.D., Joerg Koglin, M.D., Scott Korn, M.D., John M. Lachin, Sc.D., Darren K. McGuire, M.D., M.H.Sc., Michael J. Pencina, Ph.D., Eberhard Standl, M.D., Ph.D., Peter P. Stein, M.D., Shailaja Suryawanshi, Ph.D., Frans Van de Werf, M.D., Ph.D., Eric D. Peterson, M.D., M.P.H., and Rury R. Holman, M.B., Ch.B., for the TECOS Study Group*


Aim¹: the long-term effect on cardiovascular events of adding sitagliptin, a dipeptidyl peptidase 4 inhibitor, to usual care in patients with type 2 diabetes and cardiovascular disease.

Sitagliptin Cardiovascular Outcomes Study (TECOS) Study Design¹



Main inclusion criteria


- 1. Patients aged \geq 50 years with T2D
- 2. HbA_{1c} 6.5–8.0% receiving stable oral glucose-lowering therapy and/or insulin*
- 3. Pre-existing vascular disease





*50 mg daily if the baseline eGFR was ≥ 30 and < 50 mL per minute per 1.73 m^{2.} 1-N Engl J Med. 2015.16;373(3):232-42






#The primary composite cardiovascular outcome was defined as the first confirmed event of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for unstable angina. *The secondary composite cardiovascular outcome was the first confirmed event of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke. 1-N Engl J Med. 2015. 16;373(3):232-42

Conclusion:



• Among patients with type 2 diabetes and established cardiovascular disease, adding **sitagliptin** to usual care **did not** appear to increase the risk of major adverse cardiovascular events, hospitalization for heart failure, or other adverse events.







Sitagliptin: Once-Daily Dosing Administration¹

Usual Dosing for Sitagliptin*

The recommended dose of Sitagliptin is <u>100 mg once daily</u> as monotherapy or as combination therapy with metformin or a PPARγ agonist.

Patients With Renal Insufficiency*,*

A dosage adjustment is recommended in patients with moderate or severe renal insufficiency and in patients with end-stage renal disease requiring hemodialysis or peritoneal dialysis.

50 mg once daily	25 mg once daily
<u>Moderate</u>	Severe and ESRD [‡]
eGFR greater than or equal to 30	eGFR less than 30 mL/min/1.73 m2
mL/min/1.73 m2 to less than 45 mL/min/1.73	(including patients with end stage renal
m2	disease [ESRD] on dialysis)

Assessment of renal function is recommended prior to Sitagliptin initiation and periodically thereafter.

*Sitagliptin can be taken with or without food. [†]Patients with mild renal insufficiency—100 mg once daily.

[‡]ESRD=end-stage renal disease requiring hemodialysis or peritoneal dialysis.

1-Sitagliptin FDA Label, 2018, Reference ID: 4219849.

PPAR agonist = Thiazolidinedione class.



Sitagliptin + Metformin: Twice-Daily Dosing Administration¹

- Individualize the starting dose of Sitagliptin +Metformin based on the patient's current regimen.
- Adjust the dosing based on effectiveness and tolerability;
 > not exceeding the maximum recommended daily dose: (100 mg sitagliptin and 2000 mg metformin).
- Twice daily with meals, with gradual dose escalation:
- to reduce the gastrointestinal effects due to metformin.
 O Not use in eGFR <30 mL/min/1.73 m².


 \circ Not recommended in eGFR between 30 to <45 mL/min/1.73 m².

childi Diabetes

• Linagliptin Efficacy




Linagliptin is the only DPP-4 inhibitor which is primarily excreted by gut




1. Linagliptin US prescribing information, 2. Vincent SH et al. Drug Metab Dispos. 2007;35(4): 533–538, 3. He H, et al. Drug Metab. Dispos. 2009 37(3):536–544, 4. Saxagliptin US prescribing information

Linagliptin is the first only DPP-4 inhibitor that does not require dose adjustment: Easy use



1.TRAJENTA[®] EMA Summary of Product Characteristics, 2.Januvia[®] Summary of Product Characteristics. October 2016. 3.Galvus[®] Summary of Product Characteristics. June 2017.


\triangle HbA_{1c} across different background therapy Linagliptin *vs*. placebo




DIABETES

1. Therapeutic Advances in Endocrinology and Metabolism 2012, 3(4), 113–124.


Linagliptin achieves HbA1c decrease of up to 1.2% in poorly controlled patients



Significant HbA1c reductions in type 2 diabetes patients with baseline HbA1c \geq 9%




Linagliptin sustained HbA1c reduction over 104 weeks similar efficacy as a SU over 104 weeks




Linagliptin, has similar efficacy as a SU over 104 weeks






Aim: CARMELINA is a large, long-term cardiovascular (CV) outcomes trial testing the impact of linagliptin vs. placebo on top of standard care on CV and renal outcomes.

CARMELINA[®] was designed to evaluate the CV and kidney safety of linagliptin in patients with T2D¹






Higher prevalence of renal impairment CARMELINA than recent CVOTs



*eGFR ≥30 to <50 ml/min/1.73 m2; †Trial excluded patients with eGFR <30 ml/min/1.73 m² CVOT, cardiovascular outcomes trial; eGFR, estimated glomerular filtration rate DIABETES 1. Scirica BM et al. N Engl J Med 2013;369:1317; 2. White WB et al. N Engl J Med 2013;369:1327 (supplementary appendix); 3. Pfeffer MA et al. N Engl J Med 2015;373:2247 (supplementary appendix); 4. Green JB et al. N Engl J Med 2015;373:232 (supplementary appendix); 5. Zinman B et al. N Engl J Med 2015;373:2117 6. Neal B et al. Diabetes Obes Metabol 2017;19:926; 7. Marso SP et al. N Engl J Med 2016;375:311; 8. Holman RR et al. N Engl J Med 2017;377:1228

The long-term CV safety profile of linagliptin was confirmed Time to first occurrence of 3P-MACE



chiabetes


Linagliptin event rate 5.77/100 PY Placebo event rate 5.63/100 PY


Treated set, Kaplan-Meier estimate. Hazard ratio and 95% CI based on Cox regression model with terms for treatment group (p=0.7398) and region (p=0.7878); *Two-sided

3P-MACE, 3-point major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, non-fatal stroke)

Rosenstock J, et al. JAMA. 2018 Nov 9. doi: 10.1001/jama.2018.18269


Time to first occurrence of key secondary outcome: sustained ESKD, sustained decrease of ≥40% in eGFR from baseline, or death due to kidney disease






Linagliptin was associated with a significant reduction in albuminuria progression

Time to first occurrence of albuminuria progression*



There was no increased risk of hospitalization for HF with Linagliptin




Time to first occurrence of adjudication-confirmed hospitalization for HF



Overall linagliptin did not increase the risk of hypoglycemia

Hypoglycemia: rates per 100 patient-years overall



chiabetes

Dosage And Administration¹

Recommend dosing:


The recommended dose of Linagliptin is 5 mg once daily.

Linagliptin tablets can be taken with or without food.




Conclusion





1-Diabetes Obes Metab. 2011;13:841–849. 2- Diabetes Obes Metab. 2007;9:194–205. 3- Int J Clin Pract. 2010;64:562–576. 4-Diabetes Res Clin Pract. 2011;93(1):e15-75-Diabetes Care. 2019;42(Suppl 1):S90-S102. 6-N Engl J Med. 2015.16;373(3):232-42

Linagliptin Has Broad Therapeutic Indication





DIABETES



Dosage Forms and Strengths¹:

• 2.5 mg linagliptin/500 mg metformin HCl

• 2.5 mg linagliptin/1000 mg metformin HCl



Dosage and Administration¹:



Individualize the starting dose of **LIROPRIM** based on the patient's current regimen.




Give **twice** daily **with meals**, with gradual dose escalation to reduce the gastrointestinal effects due to metformin.




The maximum recommended dose is **2.5 mg linagliptin/1000 mg metformin HCI** twice daily.




Pharmacologic Approaches to Glycemic Treatment




Pharmacologic Approaches to Glycemic Management: *Diabetes Care* 2021;44(Suppl.1):S100-S110.





empaglificzin have primary heart failure outcome data.




Estimated average glucose

A1C (%)	mg/dL*	mmol/L
5	97 (76–120)	5.4 (4.2–6.7)
6	126 (100–152)	7.0 (5.5–8.5)
7	154 (123–185)	8.6 (6.8–10.3)
8	183 (147–217)	10.2 (8.1–12.1)
9	212 (170–249)	11.8 (9.4–13.9)
10	240 (193–282)	13.4 (10.7–15.7)
11	269 (217–314)	14.9 (12.0–17.5)
12	298 (240–347)	16.5 (13.3–19.3)

Data in parentheses are 95% CI. A calculator for converting A1C results into eAG, in either mg/dL or mmol/L, is available at professional.diabetes.org/eAG. *These estimates are based on ADAG data of \sim 2,700 glucose measurements over 3 months per A1C measurement in 507 adults with type 1, type 2, or no diabetes. The correlation between A1C and average glucose was 0.92 (6,7). Adapted from Nathan et al. (6).

Approach to individualization of glycemic target

Approach to Individualization of Glycemic Targets



chiabetes

Diabetes Care Volume 43, Supplement 1, January 2020

Pharmacologic Approaches to

Glycemic Treatment

AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AMERICAN COLLEGE OF ENDOCRINOLOGY

AACE/ACE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM

COPYRIGHT © 2020 AACE | MAY NOT BE REPRODUCED IN ANY FORM WITHOUT EXPRESS WRITTEN PERMISSION FROM AACE. WWW.AACE.COM/PUBLICATIONS/JOURNAL-REPRINTS-COPYRIGHTS-PERMISSIONS | DOI 10.4158/CS-2019-0472



abidi Diabetes

